CAR-T cell therapy’s promise and pitfalls: Systemic barriers to equitable cancer treatment access in global health systems
Original framing: “Treating previously untreatable cancers: How CAR-T cell therapy could be made accessible to more patients” — The Conversation - Global
The original framing omits the role of indigenous medicinal knowledge in cancer treatment (e.g., traditional African and Asian herbal therapies), historical parallels like the apartheid-era South African medical apartheid or the Tuskegee experiments, and structural causes such as patent laws (e.g., Novartis v. Union of India) that block generic production. Marginalized perspectives—from patients in LMICs to disabled communities—are erased, as are the ecological costs of biotech supply chains (e.g., rare earth mining for CAR-T production).
Medium structural omission detected in mainstream coverage.
The narrative is produced by academic and Western biotech institutions, serving the interests of pharmaceutical capital and elite research networks. Framing centers Western scientific authority while obscuring how patent regimes (e.g., TRIPS) and venture capital lock out Global South innovation. The emphasis on 'academic development' masks the extractive nature of clinical trials in low-income countries, where marginalized populations are often treated as data sources rather than beneficiaries.
Marginalized voices—including Black, Indigenous, disabled, and low-income patients—are systematically excluded from CAR-T discourse despite bearing disproportionate cancer burdens. In the U.S., Black patients are 20% less likely to access CAR-T than white patients due to referral biases and insurance barriers. Global South patients, who represent 70% of cancer deaths, are treated as 'markets' for Western therapies rather than co-creators of solutions. Disabled communities, who face higher cancer risks due to environmental toxins and healthcare discrimination, are absent from clinical trial designs. Their exclusion ensures that 'accessibility' remains a euphemism for 'affordability for the global elite.'
The CAR-T therapy narrative exemplifies how medical innovation is co-opted by neoliberal structures, where breakthroughs like CAR-T are framed as apolitical miracles while their structural exclusions—patent regimes, racialized healthcare access, and colonial-era IP laws—are rendered invisible.